Coya Therapeutics (COYA) Change in Accured Expenses (2022 - 2026)

Coya Therapeutics (COYA) has 5 years of Change in Accured Expenses data on file, last reported at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 427.91% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$703869.0 (down 203.46% YoY), and the FY2025 full-year result was $1.1 million, up 173.41% from the prior year.
• Change in Accured Expenses fell to -$1.4 million in Q1 2026, from $849207.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q4 2023 to a low of -$1.4 million in Q1 2026.
• A 5-year average of -$4476.0 and a median of $166153.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses tumbled 875.4% in 2023 and jumped 4110.61% in 2025, its largest moves.
• Tracing COYA's Change in Accured Expenses over 5 years: stood at $102751.0 in 2022, then surged by 1567.72% to $1.7 million in 2023, then tumbled by 101.24% to -$21174.0 in 2024, then jumped by 4110.61% to $849207.0 in 2025, then sank by 262.76% to -$1.4 million in 2026.
• Business Quant data shows COYA's Change in Accured Expenses at -$1.4 million in Q1 2026, $849207.0 in Q4 2025, and -$1.2 million in Q3 2025.